NASDAQ:CAI - Nasdaq - US1421521071 - Common Stock - Currency: USD
29.75
+1.16 (+4.06%)
The current stock price of CAI is 29.75 USD. In the past month the price increased by 12.22%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.7 | 349.84B | ||
AMGN | AMGEN INC | 13.22 | 154.98B | ||
GILD | GILEAD SCIENCES INC | 15.43 | 148.54B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 21.64 | 94.13B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 60.79B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 57.23B | ||
ARGX | ARGENX SE - ADR | 71.39 | 40.50B | ||
ONC | BEONE MEDICINES LTD-ADR | 4.5 | 31.19B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.84B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.28B | ||
INSM | INSMED INC | N/A | 20.78B | ||
NTRA | NATERA INC | N/A | 20.75B |
Caris Life Sciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Irving, Texas. The company went IPO on 2025-06-18. Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
CARIS LIFE SCIENCES INC
750 West John Carpenter Freeway, Suite 800
Irving TEXAS 94105 US
CEO: Timothy B. Page
Employees: 0
Phone: 18667718946
The current stock price of CAI is 29.75 USD. The price increased by 4.06% in the last trading session.
The exchange symbol of CARIS LIFE SCIENCES INC is CAI and it is listed on the Nasdaq exchange.
CAI stock is listed on the Nasdaq exchange.
10 analysts have analysed CAI and the average price target is 33.66 USD. This implies a price increase of 13.14% is expected in the next year compared to the current price of 29.75. Check the CARIS LIFE SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CARIS LIFE SCIENCES INC (CAI) has a market capitalization of 8.27B USD. This makes CAI a Mid Cap stock.
CARIS LIFE SCIENCES INC (CAI) currently has 0 employees.
CARIS LIFE SCIENCES INC (CAI) has a support level at 27.06. Check the full technical report for a detailed analysis of CAI support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CAI does not pay a dividend.
The outstanding short interest for CARIS LIFE SCIENCES INC (CAI) is 1.29% of its float. Check the ownership tab for more information on the CAI short interest.
ChartMill assigns a technical rating of 4 / 10 to CAI.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 84% to CAI. The Buy consensus is the average rating of analysts ratings from 10 analysts.